July 13, 2022
Life Sciences
  • Merck filed a lawsuit against the Biden administration to avoid potential fines for cutting off 340B contract pharmacies from getting discounted products. In 2021, Merck, along with nearly 20 drugmakers, cut off sales of 340B-discounted drugs to contract pharmacies, telling the 340B entities that if they did not join the company’s integrity program and submit claims-level data then it would no longer provide the drugs to contract pharmacies. The drugmaker charged that the policy fits within the statute for 340B, but the Health Resources and Services Administration (HRSA) disagreed and in May warned Merck for its actions. (Article here)